MONTREAL–(BUSINESS WIRE)–NuChem Therapeutics, a drug discovery and development contract research organization (CRO) located in Montreal, specializing in synthetic and medicinal chemistry services, has just completed the acquisition of Amplia Pharmatek, a drug discovery and development CRO with a focus on biology.
Amplia Pharmatek is an innovative service provider who specializes in Discovery Biology, in vivo Pharmacology, Pharmacokinetics and Toxicology.
Amplia Pharmatek and NuChem Therapeutics will form a growing team with more than 60 employees offering a wide array of integrated services.
“The combined forces of Amplia and NuChem will allow us to better serve our clients, our first priority. With our team of dedicated scientists and a brand new site built-to-suit, the future is bright” explained Marc LeBel, president. “We are very pleased to join forces with Dr. Li and the Amplia Pharmatek team. The complementarity of our two talented teams will bring synergy and a new dimension to our service offering” added Daniel Guay, CSO
“Our joint expertise will provide seamless services from lead molecule identification through the early development of drug candidates for multiple disease indications. The Amplia Team is thrilled to join the Nuchem family.” Quote Zuomei Li, Ph. D., founder of Amplia Pharmatek.
ABOUT NUCHEM THERAPEUTICS. NuChem Therapeutics offers a variety of services internationally to support the pharmaceutical and biotechnology industries, to help identify and optimize small molecule candidates for drug discovery and early development. Since its inception in 2011, NuChem has contributed to the discovery of several new drug candidates which have progressed to human clinical trials.
ABOUT AMPLIA PHARMATEK. Founded in 2009 in Montreal, Amplia Pharmatek provides preclinical drug discovery and development services in biology, including enzyme and cell-based assay development, compound screening, and in vivo pharmacology and pharmacokinetics studies.